Tag: Alder Biopharmaceuticals

May 6, 2019

Alder BioPharmaceuticals Presents New Data from Clinical Trials

Alder BioPharmaceuticals (NASDAQ:ALDR) has released new data showing consistency of early migraine prevention benefit in four clinical trials with eptinezumab....
October 23, 2018

Alder BioPharmaceuticals Announces Positive Results From Pharmacokinetic Comparability Study for Eptinezumab

Alder Biopharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced positive...
May 9, 2018

Alder BioPharmaceuticals Reports First Quarter 2018 Financial and Operating Results

Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today provided a...
April 25, 2018

Alder BioPharmaceuticals® New Data Demonstrated Eptinezumab Increased Migraine-Free Intervals and Improved Quality-of-Life Outcomes in Patients with Episodic Migraine

Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new...
April 24, 2018

Alder BioPharmaceuticals Presents New 12-Month Data of Eptinezumab in PROMISE 1 Phase 3 Trial Showing Long-Term Reduction in Episodic Migraine

Alder BioPharmaceuticals (NASDAQ:ALDR) a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced new...
February 26, 2018

Alder BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, provided a corporate...
January 29, 2018

Alder BioPharmaceuticals, Inc. Announces Offering of $200 Million of Convertible Senior Notes Due 2025

Alder BioPharmaceuticals (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an...